The global precision genomic testing market size is calculated at USD 17.89 billion in 2025 and is forecasted to reach around USD 62.34 billion by 2034, accelerating at a CAGR of 14.88% from 2025 to 2034. The North America market size surpassed USD 6.70 billion in 2024 and is expanding at a CAGR of 15.00% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Precision Genomic Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Precision Genomic Testing Market, by Product & Service
8.1.1. Consumables
8.1.1.1. Market Revenue and Forecast
8.1.2. Kits
8.1.2.1. Market Revenue and Forecast
8.1.3. Reagents
8.1.3.1. Market Revenue and Forecast
8.1.4. Equipment
8.1.5.1. Market Revenue and Forecast
8.1.5. Services
8.1.6. Market Revenue and Forecast
9.1. Precision Genomic Testing Market, by Technology
9.1.1. Next-Generation Sequencing
9.1.1.1. Market Revenue and Forecast
9.1.2. Polymerase Chain Reaction
9.1.2.1. Market Revenue and Forecast
9.1.3. Microarray Technology
9.1.3.1. Market Revenue and Forecast
9.1.4. Sanger Sequencing CRISPR/Cas Systems
9.1.4.1. Market Revenue and Forecast
9.1.5. CRISPR/Cas Systems
9.1.5.1. Market Revenue and Forecast
9.1.6. Others
9.1.6.1. Market Revenue and Forecast
10.1. Precision Genomic Testing Market, by Application
10.1.1 Oncology
10.1.1.1. Market Revenue and Forecast
10.1.2. Cardiovascular Diseases
10.1.2.1. Market Revenue and Forecast
10.1.3. Neurological Disorders
10.1.3.1. Market Revenue and Forecast
10.1.4. Reproductive Health Rare Diseases
10.1.4.1. Market Revenue and Forecast
10.1.5. Rare Diseases
10.1.5.1. Market Revenue and Forecast
10.1.6. Others
10.1.6.1. Market Revenue and Forecast
11.1. Precision Genomic Testing Market, by End Use
11.1.1. Hospitals and Clinics
11.1.1.1. Market Revenue and Forecast
11.1.2. Diagnostic Laboratories
11.1.2.1. Market Revenue and Forecast
11.1.3. Research and Academic Institutes
11.1.3.1. Market Revenue and Forecast
11.1.4. Others
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product & Service
12.1.2. Market Revenue and Forecast, by Technology
12.1.3. Market Revenue and Forecast, by Application
12.1.4. Market Revenue and Forecast, by End Use
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product & Service
12.1.5.2. Market Revenue and Forecast, by Technology
12.1.5.3. Market Revenue and Forecast, by Application
12.1.5.4. Market Revenue and Forecast, by End Use
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product & Service
12.1.6.2. Market Revenue and Forecast, by Technology
12.1.6.3. Market Revenue and Forecast, by Application
12.1.6.4. Market Revenue and Forecast, by End Use
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product & Service
12.2.2. Market Revenue and Forecast, by Technology
12.2.3. Market Revenue and Forecast, by Application
12.2.4. Market Revenue and Forecast, by End Use
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product & Service
12.2.5.2. Market Revenue and Forecast, by Technology
12.2.5.3. Market Revenue and Forecast, by Application
12.2.5.4. Market Revenue and Forecast, by End Use
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product & Service
12.2.6.2. Market Revenue and Forecast, by Technology
12.2.6.3. Market Revenue and Forecast, by Application
12.2.6.4. Market Revenue and Forecast, by End Use
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product & Service
12.2.7.2. Market Revenue and Forecast, by Technology
12.2.7.3. Market Revenue and Forecast, by Application
12.2.7.4. Market Revenue and Forecast, by End Use
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product & Service
12.2.8.2. Market Revenue and Forecast, by Technology
12.2.8.3. Market Revenue and Forecast, by Application
12.2.8.4. Market Revenue and Forecast, by End Use
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product & Service
12.3.2. Market Revenue and Forecast, by Technology
12.3.3. Market Revenue and Forecast, by Application
12.3.4. Market Revenue and Forecast, by End Use
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product & Service
12.3.5.2. Market Revenue and Forecast, by Technology
12.3.5.3. Market Revenue and Forecast, by Application
12.3.5.4. Market Revenue and Forecast, by End Use
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product & Service
12.3.6.2. Market Revenue and Forecast, by Technology
12.3.6.3. Market Revenue and Forecast, by Application
12.3.6.4. Market Revenue and Forecast, by End Use
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product & Service
12.3.7.2. Market Revenue and Forecast, by Technology
12.3.7.3. Market Revenue and Forecast, by Application
12.3.7.4. Market Revenue and Forecast, by End Use
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product & Service
12.3.8.2. Market Revenue and Forecast, by Technology
12.3.8.3. Market Revenue and Forecast, by Application
12.3.8.4. Market Revenue and Forecast, by End Use
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product & Service
12.4.2. Market Revenue and Forecast, by Technology
12.4.3. Market Revenue and Forecast, by Application
12.4.4. Market Revenue and Forecast, by End Use
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product & Service
12.4.5.2. Market Revenue and Forecast, by Technology
12.4.5.3. Market Revenue and Forecast, by Application
12.4.5.4. Market Revenue and Forecast, by End Use
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product & Service
12.4.6.2. Market Revenue and Forecast, by Technology
12.4.6.3. Market Revenue and Forecast, by Application
12.4.6.4. Market Revenue and Forecast, by End Use
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product & Service
12.4.7.2. Market Revenue and Forecast, by Technology
12.4.7.3. Market Revenue and Forecast, by Application
12.4.7.4. Market Revenue and Forecast, by End Use
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product & Service
12.4.8.2. Market Revenue and Forecast, by Technology
12.4.8.3. Market Revenue and Forecast, by Application
12.4.8.4. Market Revenue and Forecast, by End Use
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product & Service
12.5.2. Market Revenue and Forecast, by Technology
12.5.3. Market Revenue and Forecast, by Application
12.5.4. Market Revenue and Forecast, by End Use
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product & Service
12.5.5.2. Market Revenue and Forecast, by Technology
12.5.5.3. Market Revenue and Forecast, by Application
12.5.5.4. Market Revenue and Forecast, by End Use
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product & Service
12.5.6.2. Market Revenue and Forecast, by Technology
12.5.6.3. Market Revenue and Forecast, by Application
12.5.6.4. Market Revenue and Forecast, by End Use
13.1. Danaher
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Merck KGaA
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Revvity, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Maravai LifeSciences
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GenScript
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. QIAGEN
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. PacBio
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Oxford Nanopore Technologies plc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Illumina, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. 10x Genomics, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample